2:16-cv-07721 | ADAPT PHARMA OPERATIONS LIMITED et al v. TEVA PHARMACEUTICALS USA, INC. et al | Oct 21, 2016 |
2:17-cv-00864 | ADAPT PHARMA OPERATIONS LIMITED et al v. TEVA PHARMACEUTICALS USA, INC. et al | Feb 8, 2017 |
2:17-cv-02877 | ADAPT PHARMA OPERATIONS LIMITED et al v. TEVA PHARMACEUTICALS USA, INC. et al | Apr 26, 2017 |
IPR2019-00685 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00686 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00687 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00688 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00689 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00690 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00691 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00692 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00693 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00694 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00695 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00696 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00697 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00698 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
IPR2019-00699 | Nalox-1 Pharmaceuticals, LLC et al. v. Opiant Pharmaceuticals, Inc. | Feb 19, 2019 |
2:17-cv-05100 | ADAPT PHARMA OPERATIONS LIMITED et al v. TEVA PHARMACEUTICALS USA, INC. et al | Jul 12, 2017 |
2:18-cv-09880 | ADAPT PHARMA OPERATIONS LIMITED et al v. TEVA PHARMACEUTICALS USA, INC. et al | May 30, 2018 |